Submission to Pfizer Sample Clauses

Submission to Pfizer. Principal Investigator will provide any Publication to Pfizer at least 30 days before it is submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, Principal Investigator agrees to delay the disclosure for a period not to exceed an additional 60 days. a. Předložení společnosti Pfizer. Hlavní zkoušející předloží jakoukoli Publikaci společnosti Pfizer nejméně 30 dní před tím, než bude předložena ke zveřejnění nebo jinak zpřístupněna. Pokud je zapotřebí jakékoli patentové řízení s cílem ochrany práv duševního vlastnictví, Hlavní zkoušející souhlasí s odložením zveřejnění nejvýše o dodatečných 60 dnů.
View SourceView Similar (9)
Submission to Pfizer. Principal Investigator will provide any Publication to Pfizer at least 30 days before it is submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, Principal Investigator agrees to delay the disclosure for a period not to exceed an additional 60 days. a. Předložení společnosti Pfizer. Hlavní zkoušející předloží publikaci společnosti Pfizer nejpozději 30 dnů před jejím odevzdáním do tisku nebo jiným zveřejněním či sdělením. Pokud je za účelem ochrany práv k duševnímu vlastnictví vyžadován jakýkoli úkon v oblasti patentové ochrany, souhlasí hlavní zkoušející s tím, že odloží zveřejnění o dobu nepřesahující dalších 60 dnů. b. Redaction of Confidential Information. Principal Investigator will, on request, remove any previously undisclosed Confidential Information before disclosure, except for any Study- or Pfizer Drug-related information necessary to the appropriate scientific presentation or understanding of the Study results.
View Source
Submission to Pfizer. UMCU, also on behalf of the Parties and the other Partners, and ARS, as the case may be, will submit the full text of any proposed Publication to Pfizer at least thirty (30) days before it is submitted for Publication and Pfizer will reply within such thirty (30) days. Pfizer will solely have the right to propose amendments to such Publication on reasonable grounds. If Pfizer determines that Pfizer’s Confidential or patenting information is contained in such Publication, UMCU, also on behalf of the Parties and the other Partners, and ARS, as the case may be, will agree to delete that information. Should there be no comment from Pfizer within the above-mentioned period, Pfizer will be deemed to have accepted the Publication. In the event Pfizer is in the process of filing a patent application to protect intellectual property rights, Pfizer will be able to delay the Publication with a maximum of sixty (60) days. In compliance with the ENCePP Code of Conduct, UMCU, also on behalf of the Parties and the other Partners, and ARS remain free and are not obliged to take into consideration Pfizer’s comments before publication. Authorship will comply with the International Journal Committee of Medical Journal Editors (ICMJE) rules.
View Source
Submission to Pfizer. Principal Investigator will provide any Publication to
View Source

Related to Submission to Pfizer

  • Governing Law; Submission to Process EXCEPT TO THE EXTENT THAT THE LAW OF ANOTHER JURISDICTION IS EXPRESSLY ELECTED IN A TRANSACTION DOCUMENT, THIS AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS, SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW. EACH OF BIONOVA AND SAVIA HEREBY IRREVOCABLY SUBMITS ITSELF AND EACH OTHER RELATED PERSON TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE STATE OF NEW YORK AND THE COUNTY OF NEW YORK AND AGREES AND CONSENTS THAT SERVICE OF PROCESS MAY BE MADE UPON IT OR ANY OF ITS SUBSIDIARIES IN ANY LEGAL PROCEEDING RELATING TO THE TRANSACTION DOCUMENTS BY ANY MEANS ALLOWED UNDER NEW YORK OR FEDERAL LAW. EACH OF BIONOVA AND SAVIA IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF THE VENUE OF ANY SUCH PROCEEDING BROUGHT IN SUCH A COURT AND ANY CLAIM THAT ANY SUCH PROCEEDING BROUGHT IN SUCH A COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.

  • Permission to Use ‌ 5.1 Permission to use the Routes Network Rail grants the Train Operator permission to use the Routes. 5.2 Meaning References in this contract to permission to use the Routes shall, except where the context otherwise requires, be construed to mean permission: (a) to use the track comprised in the Routes for the provision of the Services using the Specified Equipment; (b) to use the track comprised in the Network in order to implement any plan established under Part H of the Network Code; (c) to make Ancillary Movements; (d) to Stable, which shall be treated, for the purposes of Part D of the Network Code, as the use of a Train Slot; (e) for the Train Operator and its associates to enter upon that part of the Network comprising the Routes, with or without vehicles; and (f) for the Train Operator and its associates to bring things onto that part of the Network comprising the Routes and keep them there, and such permission is subject, in each case and in all respects to: (i) the Network Code; (ii) the Applicable Engineering Access Statement; and (iii) the Applicable Timetable Planning Rules. 5.3 Permission under clauses 5.2(e) and 5.2(f) In relation to the permissions specified in clauses 5.2(e) and 5.2(f): (a) the Train Operator shall, and shall procure that its associates shall, wherever reasonably practicable, first obtain the consent of Network Rail, which consent shall not be unreasonably withheld or delayed; (b) the Train Operator shall remove any vehicle or other thing so brought onto any part of the Network when reasonably directed to do so by Network Rail; and (c) whilst exercising any rights conferred by clauses 5.2(e) and 5.2(f), the Train Operator shall, and shall procure that its associates shall, comply with such reasonable restrictions or instructions as Network Rail shall specify. 5.4 Changes to Applicable Engineering Access Statement and Applicable Timetable Planning Rules Changes to the Applicable Engineering Access Statement and the Applicable Timetable Planning Rules are subject to regulatory protection (including appeals) in accordance with Part D of the Network Code. 5.5 Engineering Access Statement, Timetable Planning Rules and Restrictions of Use Schedule 4 shall have effect. 5.6 The Services and the Specified Equipment Schedule 5 shall have effect. 5.7 Performance Schedule 8 shall have effect.

  • Permission to Leave Work The Employer agrees that stewards shall not be hindered, coerced, restrained or interfered with in any way in the performance of their duties, while investigating disputes and presenting adjustments as provided in this Article. The Union recognizes that each ▇▇▇▇▇▇▇ is employed by the Employer and that they will not leave their work during working hours except to perform their duties under this Agreement. Therefore, no ▇▇▇▇▇▇▇ shall leave their work without permission of their supervisor, which will not be unreasonably withheld.

  • Notification to Union The Hospital will provide the union with a list, monthly of all hirings, lay-offs, recalls and terminations within the bargaining unit where such information is available or becomes readily available through the Hospital's payroll system."

  • Notification to Employees The Employer will inform, in writing, new, transferred, temporary, promoted, or demoted employees prior to appointment into positions included in the bargaining unit(s) of the Union’s exclusive representation status. Upon appointment to a bargaining unit position, the Employer will furnish the employees with membership materials provided by the Union. The Employer will inform employees, in writing, if they are subsequently appointed to a position that is not in a bargaining unit.